REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Clinical trials for REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a new combination of drugs (PolaR-ICE) for people with diffuse large B-cell lymphoma that has come back or hasn't responded to initial treatment. The goal is to see if adding a targeted drug (polatuzumab vedotin) to standard chemotherapy can improve the chance of…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 11:27 UTC
-
Engineered immune cells take aim at Tough-to-Treat blood cancers
Disease control OngoingThis early-stage trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogn…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New drug combo shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study tested a combination of two drugs—pembrolizumab (an immunotherapy) and vorinostat (a targeted therapy)—in 52 adults with certain types of lymphoma that had returned or stopped responding to standard treatments. The main goals were to find the safest dose of…
Matched conditions: REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC